What's in Mundipharma Research GmbH & Co KG's pipeline?

Mundipharma Research GmbH & Co KG has 8 drugs in our index: 2 marketed, 0 filed, 4 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Mundipharma Research GmbH & Co KG's portfolio?

Top competitors by shared drug class: Grünenthal GmbH, Bellus Health Inc. - a GSK company, Braintree, Kati Järvelä, Purdue Pharma LP.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mundipharma-research-gmbh-co-kg.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Mundipharma Research GmbH & Co KG — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mundipharma Research GmbH & Co KG pipeline: 2 marketed, 0 filed, 4 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 4 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Laxative	Laxative	marketed	Stimulant Laxative [EPC]		Other
oxycodone naloxone tablet	oxycodone naloxone tablet	marketed	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism)	Pain Management
MR308	MR308	phase 3	P2X3 receptor antagonist	P2X3	Pain Management
Oxycodone/Naloxone Prolonged Release tablets	Oxycodone/Naloxone Prolonged Release tablets	phase 3	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism)	Pain Management
oxycodone prolonged release tablet	oxycodone prolonged release tablet	phase 3
Oxycodone & naloxone combination, prolonged release	Oxycodone & naloxone combination, prolonged release	phase 3	opioid agonist-antagonist	mu-opioid receptor	Pain management

Therapeutic area mix

Pain Management · 3
Other · 1
Pain management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Grünenthal GmbH · 2 shared drug classes
Bellus Health Inc. - a GSK company · 1 shared drug class
Braintree · 1 shared drug class
Kati Järvelä · 1 shared drug class
Purdue Pharma LP · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mundipharma Research GmbH & Co KG:

Cite this brief

Drug Landscape (2026). Mundipharma Research GmbH & Co KG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mundipharma-research-gmbh-co-kg. Accessed 2026-05-17.